Download Protocol

Open Protocols
Stamford Hospital/Medical Oncology Hematology Research
Primary
Anemia
(Chemo Induced)
Breast
Disease Stage
Met. Breast
Breast
Breast
Adjuvant
Digestive/GI
Colon
Adjuvant
Digestive/GI
Pancreatic
Recurrent or
Metastatic
Genitourinary/GU
Bladder
See Pulmonary/Lung section:
Celgene ACE-011-NSCL-001
ACORN ALSSMBC0804
Dr. Weinstein
Mary
Millennium C14007
Dr. Del Prete
Mary
NCIC MA.32
Dr. Angevine
Mary
Millennium C14007
Dr. Del Prete
Mary
Digestive/GI
Gastroesophageal
Digestive/GI
Pancreatic
Protocol
Adjuvant
Stage I or II
Resected R0 or
R1
Metastatic
Genitourinary/GU
Prostate
Genitourinary/GU
NSABP P-5
Dr. Del Prete
Ed
INCYTE INCB 18424-262
Dr. Del Prete
Ed
NewLink NLG-0405
Dr. Del Prete
Ed
CALGB 90601
Dr. Cohen
Ed
Dendron P10-3
Dr. Cohen
Mary
Sanofi-Aventis EFC11784
Title
Phase I/II Trial of Dasatinib plus Ixabepilone in 2nd or 3rd Line Metastatic
Breast Cancer
A Phase I Dose Escalation Study of MLN8237, an Aurora A Kinase
Inhibitor, in Adult Patients With Non-hematological Malignancies,
Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or
Gastroesophageal Malignancies
A Phase III Randomized Trial of Metformin versus Placebo on Recurrence
and Survival in Early Stage Breast Cancer
A Phase I Dose Escalation Study of MLN8237, an Aurora A Kinase
Inhibitor, in Adult Patients With Non-hematological Malignancies,
Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or
Gastroesophageal Malignancies
“Statin Polyp Prevention Trial in Patients with Resected Colon Cancer”
A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in
Combination with CApecitabine for Subjects with recurrent or Treatment
Refractory Metastatic Pancreatic Cancer (The RECAP trial)
A Phase III Study of Chemotherapy and Chemoradiotherapy With or
Without HyperAcute®-Pancreas (algenpantucel-L) Immunotherapy is
Subjects with Surgically Resected Pancreatic Cancer
A Randomized Doubled-Blinded Phase III Study Comparing Gemcitabine,
Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in
Patients with Advanced Transitional Cell Carcinoma
A Registry of Sipuleucel-T® Therapy in Men with Advanced Prostate
Cancer (PROCEED)
Randomized, Open Label, Multi-Center Study comparing Cabazitaxel at 25
D:\840992923.doc 11JAN12, 2FEB12, 20Feb12
Copy to D. Derdelinghen, L. Manfredo, C. Pagie, K. Radziewicz, M. Ronk, D. Sardanovic, E. Johnson
Page 1
of 3
Open Protocols
Stamford Hospital/Medical Oncology Hematology Research
Primary
Disease Stage
Prostate
Protocol
Title
Dr. Cohen
Ed
mg/m2 and at 20 mg/m2 in combination with Prednisone Every 3 Weeks to
Docetaxel in Combination with Prednisone in Patients with Metastatic
Castration Resistant Prostate Cancer not Pretreated with Chemotherapy
(Study Name: FIRSTANA)
Randomized, Open-Label Multi-Center Study comparing Cabazitaxel at 20
mg/m2 and at 25 mg/m2 Every 3 Weeks in Combination with Prednisone for
the Treatment of Metastatic Castration Resistant Prostate Cancer Previously
Treated with a Docetaxel-Containing Regimen (Study Name: PROSELICA)
Randomized Phase III Trial Comparing Everolimus Plus Placebo Versus
Everolimus Plus Bevacizumab For Advanced Renal Cell Carcinoma
Progressing After Treatment With Tyrosine Kinase Inhibitors
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin versus
Ifosfamide Plus Paclitaxel in Chemotherapy-Naïve Patients with Newly
Diagnosed Stage I-IV Persistent or Recurrent Carcinosarcoma (Mixed
Mesodermal Tumors) of the Uterus
Genitournary/GU
Prostate
Sanofi-Aventis EFC11785
Dr. Cohen
Ed
Genitourinary/GU
Renal
Metastatic
CALGB 90802
Dr. Del Prete
Sue
I-IV
GOG-0261
Dr.Del Prete
Sue
GYN
Uterus
Head & Neck
Millennium C14007
Dr. Del Prete
Mary
Hematologic
Malignancy
Celgene Connect CLL
Dr. Bar
Sue
Lymphoma
Cell Therapeutics PIX306
Dr. Angevine
Sue
Diffuse Large
B-Cell
Multiple Myeloma
Pulmonary/Lung
NSCLC
Adjuvant
IB-IIIA
CoMMpass MMRF-11-001
Dr. Bar
Sue
ECOG 1505
Dr. Del Prete
Ed
A Phase I Dose Escalation Study of MLN8237, an Aurora A Kinase
Inhibitor, in Adult Patients With Nonhematological Malignancies,
Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or
Gastroesophageal Malignancies
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
A Randomized Multicenter Study Comparing Pixantrone + Rituximab with
Gemcitabine + Rituximab in Patients with Aggressive B-Cell NonHodgkin’s Lymphoma Who Have Relapsed after Therapy with CHOP-R or
an Equivalent Regimen and are Ineligible for Stem Cell Transplant
A Prospective, Longitudinal, Observational Study in Newly Diagnosed
Multiple Myeloma (MM) Patients to Assess the Relationship between
Patient Outcomes, Treatment Regimens and Molecular Profiles
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without
Bevacizumab for Patients with Completely Resected Stage IB (≥ 4cm) – IIA
Non-Small Cell Lung Cancer (NSCLC)
D:\840992923.doc 11JAN12, 2FEB12, 20Feb12
Copy to D. Derdelinghen, L. Manfredo, C. Pagie, K. Radziewicz, M. Ronk, D. Sardanovic, E. Johnson
Page 2
of 3
Open Protocols
Stamford Hospital/Medical Oncology Hematology Research
Primary
Pulmonary/Lung
NSCLC
Disease Stage
Protocol
Locally
Advanced or
Met.
Stage III/IV
ImClone CP15-0804
Dr. Weinstein
Ed
Millennium C14007
Dr. Del Prete
Mary
Pulmonary/Lung
Pulmonary/Lung
NSCLC
Melanoma
Stage IV
Morphotek MORAb-003-009
Dr. Del Prete
Ed
Stage III/IV
E1609
Dr. Del Prete
Ed
Title
A Randomized Phase 2 Study of a Human Anti-PDGFR a Antibody
(IMC-3G3) with Paclitaxel/Carboplatin or Paclitaxel/Carboplatin Alone in
Previously Untreated Patients with Locally Advanced or Metastatic NonSmall Cell Lung Cancer
A Phase I Dose Escalation Study of MLN8237, an Aurora A Kinase
Inhibitor, in Adult Patients With Non-hematological Malignancies,
Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or
Gastroesophageal Malignancies
A Randomized, Double-Blind, Placebo-controlled, Study of the Safety and
Efficacy of Farletuzumab in Combination with Carboplatin and Paclitaxel or
Docetaxel Follow by Pemetrexed in Chemotherapy-naive Subjects with
Stage IV Adenocarcinoma of the Lung with Wild Type EGFR.
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4
Therapy Versus High-Dose Interferon α-2b for Resected High-Risk
Melanoma
D:\840992923.doc 11JAN12, 2FEB12, 20Feb12
Copy to D. Derdelinghen, L. Manfredo, C. Pagie, K. Radziewicz, M. Ronk, D. Sardanovic, E. Johnson
Page 3
of 3